Clinical trial success rates are very low, with up to 95% not succeeding, and a wide range of disease states remains ...

For companies in the biotech space, it’s never been easy to navigate the legal and business risks inherent in a highly ...

At the American Urological Association (AUA) that starts later this week, J&J is scheduled to report that TAR-200 achieved a ...

Sky Labs' CART-I ring – described as a cardio tracker – achieved 84.6% sensitivity compared to 69.1% for the Apple Watch, ...

The 6th RNA Editing Summit returns to Boston this July, bringing together 60+ experts to propel the next generation of RNA editing therapies for rare and common diseases. With momentum building from ...

This July, the 13 th Tumor Models Summit Boston returns, uniting 180+ preclinical and translational experts from biopharma ...

Roche's decision to invest heavily in the US – along with Novartis' announcement, has come hard on the heels of European ...

CSL Behring has added another major European market to the list of those providing reimbursement coverage of its haemophilia B gene therapy Hemgenix, after agreeing an access deal in Germany.

Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs. This holds especially true in the built environment — the labs ...

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage trial. The company is ...

That data analytics can help pharmaceutical firms advance their efforts – including the effectiveness of their marketing and sales teams – is clear. A McKinsey study shows that such analytics ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...